Stocktoria

Acumen Pharmaceuticals, Inc. ABOS

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-07-01

Acumen Pharmaceuticals, Inc. statistics & valuation

Market cap$170.5M
P / B2.4×
Return on equity-172.3%
Net cash$31.6M
Enterprise value USD$138.9M
Earnings yield EBIT/EV-89.2%
Return on capital-133.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
202020212022202320242025
Return on equity (%)
-44.70% -22.70% -19.60% -56.30% -172.30% 202020212022202320242025
Shares outstanding
419124 40.5M 41.0M 57.9M 60.1M 60.6M 202020212022202320242025
Net debt ($)
-$130.1M -$37.0M -$6.2M -$31.6M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-16.50% -43.70% -21.80% -16.90% -42.80% -98.80% 202020212022202320242025
Free cash flow margin (%)
202020212022202320242025
Debt / equity (×)
0.00× 0.11× 0.16× 0.32× 202020212022202320242025
EPS ($)
-$5.02 -$1.06 -$1.08 -$1.71 -$2.00 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Return on assets-98.8%-42.8%-16.9%-21.8%-43.7%-16.5%
Return on equity-172.3%-56.3%-19.6%-22.7%-44.7%39.4%
Debt / equity0.32×0.16×0.11×0.00×——
Current ratio4.076.4619.0123.0838.60—

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.